Therapies in the Pipeline for Systemic Autoimmune Diseases - European Medical Journal

Therapies in the Pipeline for Systemic Autoimmune Diseases

Download PDF
*Juan Felipe Betancur,1 Jose Fernando Molina,2 Gabriel J. Tobón3

The authors have declared no conflicts of interest.

EMJ Rheumatol. ;3[1]:118-127. DOI/10.33590/emjrheumatol/10311528.
Systemic lupus erytematosus (SLE), Sjögren’s syndrome (SS), anti-phospholipid syndrome (APS), new therapies

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


The current goals in the development of novel therapeutics of systemic autoimmune diseases are to develop agents more effective than conventional therapies as well as to reduce the risk of organ damage. To achieve this goal, large multicentre randomised controlled trials are needed to confirm the efficacy and safety of novel agents. Whether these novel modalities are synergistic to conventional drugs, the optimal dosages, and duration of treatment, need to be explored.

As expected, the development of new molecules for the treatment of autoimmune diseases is constant, and there are different ongoing clinical trials. We review the different molecules in the pipeline, summarised in Tables 1, 2, and 3. We also show the successes, failures, and molecules that require more evidence.

Please view the full content in the PDF above. 

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now